3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Dermatologic
1
Conditions
Neoplasms
17
Carcinoma, Non-Small-Cell Lung
11
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Lung Neoplasms
3
Breast Neoplasms
3
Head and Neck Neoplasms
2
Glioblastoma
2
Thrombocytosis
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Neoplasms
1
Pleural Effusion, Malignant
1
Pleural Effusion
1
Pleural Diseases
1
Oligodendroglioma
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mouth Neoplasms
1
Meningioma
1
Interventions
pembrolizumab
92
Nivolumab
56
Ipilimumab
55
Cyclophosphamide
52
Vemurafenib
28
fludarabine
27
aldesleukin
25
Interleukin-2
25
fludarabine phosphate
21
trametinib
20
dabrafenib
17
Temozolomide
14
Biopsy
14
Cisplatin
13
spartalizumab
12
atezolizumab
12
Carboplatin
11
cobimetinib
10
Specimen Handling
10
Paclitaxel
10
Introns
10
CTLA-4 Antigen
10
poly ICLC
9
binimetinib
9
Radiotherapy
9
Radiosurgery
9
MART-1 Antigen
9
tremelimumab
8
incomplete Freund's adjuvant
8
Radiation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Melanoma
×
Afatinib
×
Clear all
NCT06897735
2026-06-03
EDDIS-a1
Petrov, Andrey
Phase 1
Terminated
4 enrolled